How to Get Rid of Drusen & Manage Their Progression

No proven treatment can reliably eliminate drusen from the retina, and chasing their disappearance can actually be counterproductive. Drusen are deposits of lipids, proteins, and cellular debris that accumulate beneath (or sometimes above) the retinal pigment epithelium, and their presence is the hallmark of age-related macular degeneration. The real goal is not removal but management: slowing their growth, reducing the risk that they trigger vision-threatening complications, and catching dangerous changes early. That management relies on a combination of nutritional supplementation, lifestyle changes, regular imaging, and in some cases emerging drug therapies.

Why Drusen Form in the First Place

Drusen develop when the retinal pigment epithelium, a single-cell layer that supports the light-sensing photoreceptors, sheds debris faster than the body can clear it. That debris gets trapped between the RPE and a thin membrane beneath it called Bruch’s membrane. Over time, the trapped material triggers an immune response. Complement proteins, part of the body’s inflammatory defense system, deposit on the accumulated debris and ramp up local inflammation, which in turn attracts more protein and lipid buildup.¹ Lab models have shown that one of the key players is apolipoprotein E, a lipid-transport protein produced by RPE cells, which forms the scaffolding around which drusen grow. Once that scaffold is exposed to blood serum, additional drusen-associated proteins and terminal complement complexes accumulate on it, driving a self-reinforcing cycle of deposit growth and inflammation.²

Inflammatory markers like IL-1β are found in significantly higher concentrations in the retinas and Bruch’s membranes of older eyes, especially those with clinically significant drusen.³ This chronic, low-grade inflammation is what makes drusen dangerous. They are not inert blobs sitting passively under the retina; they are active sites of immune activity that can destabilize the tissue above them.

Not All Drusen Are the Same

Your eye doctor’s level of concern depends heavily on what type of drusen you have. Small, hard drusen with well-defined edges are extremely common in people over 50 and carry minimal risk on their own. Large, soft drusen with indistinct borders are a different story: they indicate intermediate AMD and substantially raise the odds of progressing to vision-threatening late AMD. The most dangerous combination appears to be soft drusen together with subretinal drusenoid deposits. In one study following the fellow eyes of people who already had wet AMD in one eye, that combination carried roughly an 18-fold higher risk of developing new abnormal blood vessel growth compared to eyes without drusen.⁴

Subretinal drusenoid deposits, sometimes called reticular pseudodrusen, deserve special attention because they sit in a different location from conventional drusen. While standard drusen form beneath the RPE, these deposits accumulate above it, in the space between the RPE and the photoreceptors.⁵ They tend to appear in eyes with thinner choroids (the blood-vessel-rich tissue behind the retina) and are strong independent risk factors for geographic atrophy and a specific type of abnormal blood vessel growth called type 3 neovascularization.⁶ They are dynamic structures that can grow, merge together, or regress, and they are easy to miss on a standard eye exam. Specialized imaging, particularly optical coherence tomography, is needed to detect them reliably.⁷

The Paradox of Drusen Regression

One of the most counterintuitive facts about drusen is that their disappearance is not necessarily good news. Spontaneous drusen regression, where large soft drusen seem to flatten and fade on imaging, has been associated with the development of geographic atrophy, the “dry” form of advanced AMD in which patches of RPE cells die off permanently.⁸ In one study, roughly three-quarters of eyes that developed geographic atrophy had it preceded by a drusen collapsing, often from a large dome-shaped elevation of the RPE called a drusenoid pigment epithelial detachment.⁹

This is why “getting rid of drusen” as a treatment goal can be misleading. A drusen that collapses may simply indicate that the RPE beneath it has died, leaving behind an area of permanent vision loss. Any legitimate treatment needs to stabilize the retinal tissue, not just shrink the deposits. Imaging follow-up after any apparent drusen regression is essential to check whether the underlying RPE is still intact.

What AREDS2 Supplements Actually Do

The most widely recommended intervention for people with intermediate AMD is the AREDS2 formula: a combination of vitamins C and E, zinc, copper, lutein, and zeaxanthin. The original AREDS trial established that a similar formula reduced the risk of progressing to advanced AMD by about a quarter, and the AREDS2 follow-up trial refined the recipe by swapping out beta-carotene (which raised lung cancer risk in smokers) for lutein and zeaxanthin.

At 10 years of follow-up, people taking lutein and zeaxanthin had a modest but statistically meaningful reduction in progression to late AMD compared to those who did not.¹⁰ The benefit was strongest compared to beta-carotene, with about a 15% lower risk of progression when the two were compared head to head. Omega-3 fatty acids (DHA and EPA), despite promising observational data, did not show a significant benefit in the randomized trial setting.¹¹

A few things worth noting: these supplements slow progression to late AMD. They do not reverse existing drusen, and they are not recommended for people who only have small drusen or no AMD at all. If your eye doctor has told you that you have intermediate AMD in at least one eye, the AREDS2 formula is the single most evidence-backed thing you can take. If you have only a handful of small, hard drusen, the formula has not been shown to help and is unnecessary.

Diet and Lifestyle Beyond Supplements

Supplementation aside, the broader pattern of what you eat and how you live matters. Prospective studies show that diets rich in lutein, zeaxanthin, and omega-3 fatty acids, particularly through green leafy vegetables, fatty fish, and Mediterranean-style eating, are associated with a 20% to 56% reduction in AMD progression risk across different disease stages. Smoking cessation, maintaining a healthy weight, and regular physical activity also appear to be protective.¹²

Smoking is the single most consistently identified modifiable risk factor for AMD. If you have drusen and still smoke, quitting is likely more impactful than anything else on this list. Weight management matters in part because visceral fat is metabolically active and contributes to systemic inflammation, the same kind of chronic inflammatory process that drives drusen growth at the back of the eye.

Laser Treatment and Why It Is Not Standard of Care

The idea of using a laser to clear drusen is appealing and has been tested repeatedly. Early trials in the 1990s and 2000s showed that certain laser treatments could physically reduce drusen, but without any benefit to vision or AMD progression. The most rigorous recent test was the LEAD trial, which used a subthreshold nanosecond laser, a gentler approach designed to stimulate the RPE without burning it. Overall, the laser did not significantly slow progression to late AMD compared to sham treatment.¹³

An interesting wrinkle emerged in a post hoc analysis: among the roughly three-quarters of participants who did not have reticular pseudodrusen at the start, the laser appeared to substantially slow progression. But in those who did have pseudodrusen, the laser was associated with an increased rate of progression. Because this was a subgroup finding discovered after the fact rather than a planned comparison, it is not strong enough to base treatment decisions on. It does, however, reinforce the idea that pseudodrusen and conventional drusen behave differently and may need different management strategies. No laser treatment for drusen is currently approved or widely recommended.

Statins and Drusen Regression

Because drusen contain lipids and cholesterol, researchers have wondered whether cholesterol-lowering statin drugs might help. A small prospective study using high-dose atorvastatin (80 mg daily) in people with large soft drusen found that roughly 10 out of 23 participants experienced drusen regression, along with a modest improvement in visual acuity, and none progressed to wet AMD during the study period.¹⁴

These results are intriguing but very preliminary. The study was small, had no control group receiving a placebo, and the follow-up was limited. Larger observational studies on statins and AMD have produced mixed results, with some suggesting a modest benefit and others finding no clear effect. For now, no one should start high-dose statins specifically for drusen. If you are already on a statin for cardiovascular reasons, that is fine, and it might offer some incidental eye benefit, but the evidence is not yet strong enough to make drusen an independent reason to take one.

Complement Inhibitors for Geographic Atrophy

Since complement-driven inflammation is central to drusen formation and the progression from drusen to geographic atrophy, drugs that block the complement cascade have been a major focus of pharmaceutical development. Two complement inhibitors, pegcetacoplan and avacincaptad pegol, have been approved in some markets for treating geographic atrophy. These are injected directly into the eye on a regular schedule.

A network meta-analysis of randomized trials found that both drugs significantly slowed the growth of atrophic lesions compared to sham injections.¹⁵ The effects are real but modest: they slow the rate at which atrophic patches expand, rather than stopping or reversing them. They are also indicated for geographic atrophy specifically, not for earlier stages of AMD where drusen are present but atrophy has not yet developed. Their role in drusen management is therefore indirect: they represent the first targeted therapies for what happens after drusen progress to their most damaging endpoint.

Why Monitoring Matters More Than Most People Think

Standard visual acuity, the letters-on-a-chart test, often stays normal well into intermediate AMD. By the time you notice you cannot read the eye chart, significant damage has already occurred. More sensitive measures of visual function decline much earlier. Drusen volume is associated with worse performance on contrast sensitivity, low-luminance visual acuity, and the ability to see under dim lighting conditions.¹⁶

Dark adaptation, the process by which your eyes adjust to dim light after being exposed to a bright flash, is one of the earliest functions to deteriorate in AMD. The rate at which dark adaptation slows tracks with disease severity and gets dramatically worse in eyes with subretinal drusenoid deposits.¹⁷ People with pseudodrusen in particular have deeply impaired dark adaptation, with the vast majority hitting the ceiling of the test instrument, meaning their ability to see in the dark is essentially maxed out in terms of how delayed it is.¹⁸ If you have noticed that driving at night has become harder or that adjusting to a dark room takes much longer than it used to, mention it to your eye doctor; it may be an early sign of drusen-related retinal changes.

Multimodal imaging is increasingly considered the standard for proper monitoring. A regular color photograph of the back of the eye cannot distinguish between a drusen sitting harmlessly under intact retinal tissue and one that has already caused the overlying photoreceptors to degenerate.¹⁹ Optical coherence tomography and autofluorescence imaging together reveal a much more detailed picture of what is happening at the cellular level. If you are being monitored for intermediate AMD, ask your provider whether they are using OCT-based imaging at your visits.

AI Tools and Predicting Which Eyes Will Get Worse

One of the biggest challenges in drusen management is that most eyes with intermediate AMD never progress to vision-threatening disease, but a meaningful minority do, and predicting which eyes will convert is difficult. Artificial intelligence models trained on OCT scans are getting remarkably good at this. One model combining imaging features with clinical data achieved an accuracy above 0.96 for predicting whether a non-exudative AMD eye would develop abnormal blood vessel leakage within three months.²⁰ Another approach using automated reading of OCT scans combined with electronic health record data predicted conversion to wet AMD within two years with strong discrimination.²¹

These tools are not yet part of routine clinical care for most patients, but they are moving in that direction. The practical implication is that future management of drusen may involve AI-generated risk scores that tell your eye doctor how closely to monitor you and when to start treatment. For patients, this could mean fewer unnecessary visits for stable eyes and earlier intervention for eyes heading toward trouble.

Drusen Outside of Age-Related Macular Degeneration

Not all drusen are AMD-related. Optic disc drusen, for example, are calcified deposits that form within the optic nerve head rather than beneath the macula. They are a completely separate entity, though one small study noted a higher rate of macular AMD in people with optic disc drusen compared to those without, suggesting there could be some shared susceptibility.²² That association did not reach statistical significance, so it remains speculative.

Retinal drusen also show up in certain kidney diseases. In conditions involving overactivation of the complement system, such as C3 glomerulopathy and dense deposit disease, drusen-like deposits can appear in the retina at much younger ages than typical AMD. All subjects with dense deposit disease in one study had retinal drusen and impaired night vision.²³ This overlap between kidney and eye disease underscores that drusen are not just an aging phenomenon but a byproduct of complement dysregulation, which can have systemic roots. If you are young and have been told you have drusen, your doctor should consider whether an underlying systemic condition like complement-mediated kidney disease might be involved.

A Practical Framework for Managing Drusen

Given everything above, here is what drusen management realistically looks like at different stages:

Small, hard drusen only: No treatment is needed. These are present in most people over 50. A routine dilated eye exam every one to two years is sufficient.
Intermediate AMD (large soft drusen, pigment changes): Start the AREDS2 supplement formula. Prioritize a Mediterranean-style diet, quit smoking if applicable, and maintain a healthy weight. Get OCT imaging at your visits. Use an Amsler grid at home to check for sudden changes in your central vision.
Subretinal drusenoid deposits detected: These warrant closer follow-up, potentially every three to six months, since they are associated with faster progression and particular types of advanced disease. Be aware that night vision difficulties may reflect real retinal changes, not just aging.
Geographic atrophy present: Complement inhibitor injections are now an option and can slow lesion growth, though they require ongoing eye injections and are not a cure. Discuss with a retina specialist whether the potential benefit justifies the treatment burden.
Wet AMD conversion: Anti-VEGF injections remain the standard of care and can preserve or improve vision if started promptly. Monitoring for sudden symptoms like distorted lines or a dark spot in your central vision is critical.

The frustrating reality is that there is no pill, laser, or procedure that makes drusen safely vanish. But the evidence-based toolkit for slowing things down is more substantial than many people realize, and the emerging complement inhibitors and AI-driven monitoring tools suggest the next decade will bring considerably more options. The single most productive thing you can do right now is make sure you are getting proper imaging-based follow-up and taking the supplements appropriate to your stage of disease.